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Spain and 7) George Washington University, Washington, DC, USAAbstractDrug resistance mutations compromise the success of antiretroviral treatment in human immunodeﬁciency virus type 1 (HIV-1)-infected
children. We report the virologic and clinical follow-up of the Madrid cohort of perinatally HIV-infected children and adolescents after
the selection of triple-class drug-resistant mutations (TC-DRM). We identiﬁed patients from the cohort carrying HIV-1 variants with TC-
DRM to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors and protease inhibitors according to
IAS-USA-2013. We recovered pol sequences or resistance proﬁles from 2000 to 2011 and clinical– immunologic–virologic data from the
moment of TC-DRM detection until December 2013. Viruses harbouring TC-DRM were observed in 48 (9%) of the 534 children and
adolescents from 2000 to 2011, rising to 24.4% among those 197 with resistance data. Among them, 95.8% were diagnosed before 2003,
91.7% were Spaniards, 89.6% carried HIV-1-subtype B and 75% received mono/dual therapy as ﬁrst regimen. The most common TC-
DRM present in 50% of them were D67NME, T215FVY, M41L and K103N (retrotranscriptase) and L90M (protease). The susceptibility
to darunavir, tipranavir, etravirine and rilpivirine was 67.7%, 43.7%, 33.3% and 33.3%, respectively, and all reported high resistance to
didanosine, abacavir and nelﬁnavir. Despite the presence of HIV-1 resistance mutations to the three main antiretroviral families in our
paediatric cohort, some drugs maintained their susceptibility, mainly the new protease inhibitors (tipranavir and darunavir) and
nonnucleoside reverse transcriptase inhibitors (etravirine and rilpivirine). These data will help to improve the clinical management of
HIV-infected children with triple resistance in Spain.
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immunodeﬁciency virus (HIV), including 2.5 million children
younger than 15 years old (http://www.who.int/hiv/pub/me/
unaids_global_report/en/). Access to antiretroviral treatment
(ART) has changed the course of infection, reducing morbidity,Clin Microbiol Infect 2015; 21: 605.e1–605.e9
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.02.003
605.e2 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMImortality and HIV viremia, as well as increasing the life expec-
tancy of HIV-infected adults and children [1,2]. New effective
combination therapies have improved clinical outcome and
increased thresholds for development of drug resistance muta-
tions (DRMs). Development of new antiretroviral (ARV) ther-
apy has increased treatment options in children [3]. However,
over 100 mutations conferring different levels of resistance to
one or more ARV have been identiﬁed in the HIV-1 genome [4].
According to international guidelines [5] (http://www.who.
int/hiv/pub/guidelines/arv2013/download/en/), ﬁrst-line ART
for HIV-1-infected children and adults is a combination of two
nucleoside reverse transcriptase inhibitors (NRTIs) and a third
agent from a different class, either a nonnucleoside reverse
transcriptase inhibitor (NNRTI) or a ritonavir-boosted prote-
ase inhibitor (PI). ART failure with NRTI/NNRTI combination
occurs in 10% to 30% of patients per year, mainly associated
with NRTI and/or NNRTI resistance (http://apps.who.int/iris/
bitstream/10665/75202/1/WHO_HIV_2012.17_eng.pdf) [6,7].
Although the number of children receiving ART is
increasing worldwide, improving their survival, children are at
greater risk of developing ARV resistance [8,9], compromising
the success of present and future treatment options. The
extensive resistance mutations to the three main ARV families
(TC-DRM) in HIV-infected patients frequently leads to
phenotypic or genotypic resistance to at least one drug from
all three original ARV classes (NRTIs, NNRTIs and PIs) [10]. It
is associated with poor prognosis, together with low CD4+ T
cell count and high viremia at the time of the triple-class failure
and death [11].
Since the beginning of the HIV epidemic in Spain, 534 pa-
tients have been registered in the Madrid cohort of HIV-1-
infected children and adolescents established in 2003, repre-
senting 51.4% of the infected paediatric population registered in
the country by December 2013. We report the virologic and
clinical follow-up of the cohort after the detection of selected
triple-class drug-resistant viruses.Materials and methodsStudy population
Patients from the Madrid cohort of HIV-infected children and
adolescents (n = 534) carrying HIV-1 variants with TC-DRM
were identiﬁed. We recovered pol sequences or available
resistance proﬁles from each patient from March 2000 to
December 2011, recording epidemiologic, clinical and virologic
data (virus load, HIV-1 variant and resistance mutations when
TC-DRM was detected). Evolution of virus load, CD4 count,
ART regimens and drug susceptibility were recorded from the
moment of TC-DRM detection until December 2013.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectHIV-1 pol sequencing
HIV-1 RNA extraction, ampliﬁcation and sequencing were
performed in the pol coding region (1121 bp) as previously
reported [12]. Samples from patients were kindly provided by
the Paediatric HIV BioBank integrated in the Spanish AIDS
Research Network [13]. All patients provided informed con-
sent, and protocols were approved by institutional ethical
committees.
Drug resistance analysis
We selected patients according to their pol sequence, genotypic
resistance proﬁle or sample availability by December 2013.
Most genetic sequences and genotypic resistance proﬁles have
been previously reported [14] or were recovered from clinical
routine drug-resistance tests. DRMs in pretreated patients
were deﬁned by the International AIDS Society–USA (IAS) list
[4]. Drug susceptibility was predicted using the Stanford HIVdb
algorithm (http://sierra2.stanford.edu/sierra/servlet/JSierra),
which classiﬁes drug susceptibility in four categories depending
on mutation scores: susceptible, low-level, intermediate and
high-level resistance. Clinical data related to virologic and
immunologic situation (evolution of virus load, CD4 counts,
ART regimens and drug susceptibility) of each selected patient
with TC-DRM experience were recorded from the moment of
TC-DRM detection until December 2013.ResultsTC-DRM viruses selection
Viruses harbouring TC-DRM were observed in 48/534 (9%)
children and adolescents from the entire cohort from 2000 to
2011. However, the percentage rose to 24.4% among those
197 with resistance data. The total of 158 pol sequences and 62
genotypic resistance proﬁles were available for the 48 patients
and ranged from 1 to 24 sequences per proﬁle per patient. For
the study, we selected the ﬁrst sequence or genotypic resis-
tance proﬁle when TC-DRM was detected and the last available
per patient before December 2013. Hence, in the analysis, we
used a total of 63 pol sequences and 18 genotypic resistance
proﬁles available until December 2013. TC-DRM prevalence
decreased over time: 70.8% (2000–2004) versus 29.2%
(2005–2011).
Clinical features of the study population
Clinical and epidemiologic features of the 48 HIV-1 prenatally
infected children collected until December 2013 are listed in
Table 1. Among these 48 patients with TC-DRM, 91.6% were
Spaniards and 89.6% carried subtype B. Among those with
diagnosis data, 95.8% were diagnosed before 2003.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e1–605.e9
TABLE 1. Baseline features of 48 HIV-1 infected children and
adolescents from the Madrid cohort harbouring triple
resistance
Characteristic Value
Origin, n (%)a,b
Spain 44 (91.6%)
Africa 2 (4.2%)
America 2 (4.2%)
Infected HIV-1 variants, n (%)
Subtype B 43 (89.6%)
Diagnosis year, n (%)c
1987–1993 20 (43.5%)
1994–2004 26 (56.5%)
First ART regimen, n (%)
NRTI 28 (58.3%)
2 NRTIs + PI 11 (22.9%)
2 NRTIs 8 (16.7%)
2 NRTIs + NNRTI 1 (2.1%)
2 NRTIs + NNRTI + PI 0
Year of appearance of TC-DRM, n (%)d
2000 11 (22.9%)
2001–2004 23 (47.9%)
2005–2008 8 (16.7%)
2009–2011 6 (12.5%)
ART experience, n (%)h
NRTIs 37 (100%)
NNRTIs 31 (83.8%)
PIs 37 (100%)
No. of regimen switchesh
Mean (range) 6.8 (1–13)
1–2, n (%) 8 (21.6%)
3–6, n (%) 24 (64.9%)
7–12, n (%) 5 (13.5%)
No. of previous drugsh
Mean (range) 9.5 (3–18)
<3, n (%) 0
3–6, n (%) 7 (18.9%)
7–13, n (%) 25 (67.6%)
>13, n (%) 5 (13.5%)
Age at diagnosis (months), median (range)c 20 (0–122)
Age at ﬁrst ART regimen, median (range)d 37.7 (0–122)
Age at TC-DRM ﬁrst detection (years),
median (range)
10.5 (1–26)
Time of ART duration, median (range) 12.9 years (2 months–19 years)
VL (c/mL), median (IQR)c 42 028 (4574–98 250)
CD4, median (IQR)e 25.5% (18–33%)
CD8, median (IQR)f 43.5% (34–52%)
CD4/CD8, median (IQR)g 0.5 (0.3–0.7)
ART, antiretroviral treatment; IQR, interquartile range; NNRTI, nonnucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; TC-DRM, mutations to the three main ARV families; VL, virus
load.
Rates calculated with available data in 46c, 40d, 44e, 42f, 28g and 37h HIV-1 infected
children with TC-DRM, respectively.
aCountries of origin: Spain (n = 44), Equatorial Guinea (n = 1), Mozambique (n = 1),
Guatemala (n = 2).
bPatient distribution among hospitals in Madrid, Spain; Hospital Universitario La Paz
(n = 14), Hospital Universitario 12 de Octubre (n = 14), Hospital Universitario
Carlos III (n = 5), Hospital Universitario de Getafe (n = 6), Hospital Universitario
Gregorio Marañón (n = 5), Hospital Universitario Príncipe de Asturias (n = 2),
Hospital Niño Jesús (n = 1), Hospital Universitario de Móstoles (n = 1).
CMI Rojas Sánchez et al. Triple HIV resistance in Madrid 605.e3Monotherapy or dual therapy had been received as ﬁrst
regimen by 75% and triple therapy by 25%. Among the last
group, one (8.33%) received NNRTI-based triple therapy and 11
(91.7%) received PI-based triple therapy, including unboosted
nelﬁnavir (NFV) in 4 cases and lopinavir/ritonavir (LPV/r) in one
child. None of the remaining patients was treated with boosted
indinavir (IDV), saquinavir (SQV), amprenavir (APV), fosam-
prenavir (FPV), tipranavir (TPV) or darunavir (DRV). The mean
age when TC-DRM was detected for the ﬁrst time was 10.5
years, and most of the patients (87.5% of 48) developed TC-
DRM before 2009. All patients were receiving ART when theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inﬁrst HIV pol sequence was available. The mean age at the start of
ART was nearly 3 years. More than 50% of the patients received
zidovudine (ZDV) as ﬁrst-line therapy using 16 different com-
binations, most frequently 2NRTIs plus one PI (Table 1).
Until December 2013, patients with TC-DRM experience in
the cohort showed ART duration for a mean of 13 years. There
were frequent regimen switches (mean 6.8) and high drug
experience (mean 9.5 drugs, range 3–18 drugs) (Table 1). Up to
80% had received at least one drug prescribed off label ac-
cording to the European Medicines Agency. By December
2013, nearly 44% (21 of 48) of the patients from the study
cohort with TC-DRM experience had been transferred to adult
units: two before TC-DRM was detected, two at TC-DRM
detection and 17 after TC-DRM identiﬁcation. Twenty-ﬁve
children still remain under follow-up in paediatric units, one
died and another was lost to clinical follow-up.
In December 2013, we recorded the latest available virologic
and clinical features of the 48 HIV-1-infected patients with TC-
DRM detection. In more than 50% of the patients, the latest
clinical follow-up was before 2012 (Table 2). The majority
(47.9%) were young adults (>18 years old), and 17 (73.9%) of
them were receiving follow-up in adult units. Twenty-eight
patients (58.3%) with TC-DRM resistance presented unde-
tectable virus load, reaching 50 plasma HIV-1-RNA copies/
mL. Of the 44 patients with available CD4+ T cell data, 36.4%
had CD4+ counts of >750 cells/mm3, and 65.9% had >500
CD4+ T cells. Also, among the 39 patients with available CD4
and CD8 data, 20.9% had normal CD4/CD8 (1) ratio
(Table 2), suggesting good immunologic status.
Prevalence of HIV-1 drug resistance mutations and
drug susceptibility
Among the 378 major DRMs found among the 48 HIV-1-
infected patients when triple-drug resistance was found,
48.4% of them were related to NRTIs, 29.6% to PIs and 21.9%
to NNRTIs. The most common TC-DRMs present, in 50% of
the 48 patients receiving retrotranscriptase, were D67NME,
T215FVY and M41L for NRTIs, K103N for NNRTIs and L90M
at protease for PIs (Fig. 1). However, despite having TC-DRM,
we observed a preserved susceptibility to several drugs within
these three ARV families. In fact, among the 48 children with
TC-DRM, the Stanford HIVdb algorithm predicted susceptibility
to DRV in 32 (66.7%) children, to TPV in 21 (43.7%) and to
etravirine (ETV) and rilpivirine (RPV) in 16 each (33.3%) (Fig. 1).
The Stanford HIVdb algorithm predicted susceptibility to ABC
and ddI in only one (2.1%) patient, and all the 48 children
presented high resistance to NFV.
Among patients with available pol sequences or genotypic
resistance proﬁle, 54% carried a T215Y mutation and had both
resistance to ABC and high resistance level to AZT and d4Tfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e1–605.e9
TABLE 2. Virologic and immunologic situation of 48 patients with TC-DRM experience in the last available clinical data recorded
until December 2013
Last clinical
follow-up
No. of
patients
Age (years)
at last visit,
median (range)
VL (mL), median
(range)
No. of patients
CD4/CD8c
ratio
With virus
suppression £50 c/mL
With virus failure (c/mL)
With ‡500
CD4/mm3a
With
CD4/CD8 ‡ 1b>103–104 >104–105 >105
2013 12 19.2 (14–29) 21 (20–121635) 9 1 1 1 6 4 0.9
2012 8 17.9 (9–25) 30.5 (20–29400) 5 2 1 0 6 2 1.8
2011 8 19.1 (15–24) 41.5 5 1 2 0 4 2 0.6
2010 5 17.2 (15–19) 19552 (50–150000) 2 0 1 2 2 0 0.5
2008 4 11.5 (6–19) 50 (50–90375) 3 1 0 0 2 0 0.4
2007 3 19.7 (18–21) 50 (50) 3 0 0 0 3 1 1
2006 1 15 247948 0 0 0 1 1 0 0.2
2005 2 18.9 (16–21) 23632 (34742–12522) 0 0 2 0 1 0 0.5
2004 1 8 11000 0 0 1 0 1 0 0.3
2003 2 6.4 (2–12) 420104
(100000–740208)
0 0 0 2 1 0 0.0
2000 2 4.7 (3–7) 2975 (50–5900) 1 1 0 0 2 NA NA
2000–2013 48 (100%) 16.5 (2–29) 50 (20–740208) 28 (58.3%) 6 (12.5%) 8 (16.7%) 6 (12.5%) 29 (65.9%) 9 (20.9%) 0.9
NA, data not available; VL, virus load.
aAmong the 44 patients with available CD4+ T cell data: CD4 range 1% to 53%; CD4+ T cell range 19 to 2578.
bMean among the 43 patients with available CD8+ T cell data: CD8 range 22% to 80%; TC8+ T cell range 108–2204.
cMean among the 39 patients with available CD4/CD8 data; CD4/CD8 ratio range 0.01 to 1.8.
605.e4 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIwhen M41L substitution was present. More than half of the 48
patients presented K103N/S, and all of them had EFV and NVP
experience. For PIs, L90M and M46L only presented a low-
resistance level to LPV, according to Stanford interpretation.
Seventy percent of these children carried 5 or more minor PIs
mutations, ranging from 2 to 10 (Fig. 2).
Longitudinal follow-up
Thirty-ﬁve of the 48 HIV-infected children with triple class
resistance presented additional pol sequences or genotypic
resistance proﬁle after the ﬁrst TC-DRM detection until
December 2013 (Supplementary Fig. 1). The mean time be-
tween these two available sequences was 51.7 months. During
this time, DRMs to at least one ARV family reverted to wild-
type (wt) residue in 15 (42.8% patients; P3, P9, P10, P11,
P12, P15, P17, P27, P28, P34, P36, P37, P42, P44, P47) of 35
children with TC-DRM and longitudinal sequences.
Considering ARV families, DRMs to NNRTIs reverted to
wt in 9 children (patients P3, P9, P10, P15, P17, P34, P36, P42,
P44), all recovering complete drug susceptibility to NVP and
EFV according to the Stanford prediction (Supplementary
Fig. 1). Additionally, two patients (patients P25 and P33)
recovered susceptibility to NVP and EFV despite carrying
V90I and E138A substitutions, respectively. All DRMs to
NRTIs reverted to wt in 4 children (patients P3, P11, P28,
P36), who recovered drug susceptibility to all NRTIs. Patient
P16 recovered susceptibility to 3TC and FTC, although an
M41L mutation was detected. Resistance to PIs reverted in
nine patients (patients P3, P10, P12, P17, P27, P28, P34, P37,
P47), all of whom experienced improved susceptibility to
most PIs (Supplementary Fig. 1).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectDiscussionTo our knowledge, this is the ﬁrst study to describe the clinical
and virologic features of HIV-1-infected children and adoles-
cents from the Madrid cohort with experience of infection with
TC-DRM viruses. By December 2013, 144 (26.9%) of the 534
patients in the entire Madrid cohort of HIV-1-infected children
and adolescents were under follow-up. They were mainly
infected by HIV-1 subtype B (82%), with a median age of nearly
15 years. A total of 147 (27.5%) had been transferred to adult
units, 156 (29.2%) had died and 87 (16.3%) had been lost to
follow-up. By December 2013, most (95.5%) children under
follow-up were receiving highly active ART. Among them,
93.9% were receiving NRTIs, 48.5% NNRTIs and 62.1% PIs.
The most commonly used ART (rates 40%) in the study
cohort were ABC, 3TC, FTC, TDF, EFV, RTV, and LPV/r. New
ARV were used: DRV (27%), ATV (13%), raltegravir (RTG,
12%), ETV (9%) and maraviroc (MRV, 4%). This study reveals
that nearly one of every 4 HIV-1-infected children and ado-
lescents with resistance data carried TC-DRM and had been
heavily exposed to the three main ARV families, many of them
receiving suboptimal regimes or inadequate drug dosing, as in
other paediatric cohorts [15]. The prevalence found is higher
than that reported in previous studies worldwide [8], including
other European [9] or US paediatric cohorts (Russell et al.,
personal communication).
The higher rate of children carrying triple resistance found
during 2000–2004 may be due to the higher number of HIV-1
paediatric diagnoses during that period and to the reduced
availability of approved ARV for therapeutic use in childrenious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e1–605.e9
FIG. 1. DRM prevalence across ARV families and rate of patients with predicted susceptibility to each ARV in the 48 HIV-1 infected patients when TC-
DRM was ﬁrst detected. DRM, drug resistance mutation; ARV, antiretroviral. DRM and predicted susceptibility levels to each ARV drug according to
the Stanford HIVdb algorithm. 3TC, lamivudine; ATV, atazanavir, NFV, nelﬁnavir; AZT, zidovudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz;
ETV, etravirine; FPV, fosamprenavir; FTC, emtricitabine; ABC, abacavir; IDV, indinavir; LPV, lopinavir; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor. d4T, stavudine; RPV, rilpivirine; SQV, saquinavir;
TDF, tenofovir; TPV, tipranavir.
CMI Rojas Sánchez et al. Triple HIV resistance in Madrid 605.e5compared to recent years [9,16,17]. Most of them have expe-
rienced monotherapy or dual therapies, which led to treatment
failure due to the incomplete virus suppression, reducing ART
efﬁcacy after DRM selection [18]. With newer ARV therapies
such as enfuvirtide, ATV, FPV, TPV, DRV, MRV and RTG, a
reduction in the number of children carrying TC-DRM was
observed.
Our study has shown that DRMs can revert with new potent
ARV regimens in previously affected children carrying TC-Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InDRM, leading to drug susceptibility to certain previously
affected drugs. However, because DRMs can be achieved in
proviral DNA maintaining undetectable levels in plasma [19],
we cannot exclude the notion that viruses with TC-DRM can
preexist at low levels and reemerge if suppression is not
complete, reappearing in new virus sequences despite their
previous reversion.
All 48 selected patients with TC-DRM experience were
receiving ART, and 72.9% had received three to 13 differentfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e1–605.e9
FIG. 2. ARV susceptibility among 48 HIV-1 infected patients when triple resistance was ﬁrst detected. Color code: green, susceptible; blue, low-level
resistance; yellow, intermediate resistance; red, high-level resistance. The percentage shows susceptibility to ARV drugs among 48 patients predicted
by Stanford’s HIVdb algorithm. 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz;
ETV, etravirine; FPV, fosamprenavir; FTC, emtricitabine; IDV, indinavir; LPV, lopinavir; NFV, nelﬁnavir; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor. d4T,stavudine; RPV, rilpivirine; SQV, saquinavir;
TDF, tenofovir; TPV, tipranavir.
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FIG. 2. (continued).
CMI Rojas Sánchez et al. Triple HIV resistance in Madrid 605.e7ART regimens when TC-DRM appeared. All 48 presented a
good immunologic and clinical situation at the last visit; 65.9%
presented 500 CD4+ T cells, and 58.3% experienced virus
suppression. It is of note that, comparing to the entire paedi-
atric cohort by December 2013, TC-DRM cohort presented
lower rate of patients with 500 CD4+ T cells (65.9% vs.
81.3%) and undetectable virus load (58.3% vs. 82.6%) and higher
number of regimen switches (mean 6.8 (range 1–13) vs. 4
(range 2.5–7)).
However, most of the patients with TC-DRM failed to
normalize the CD4/CD8 ratio despite ART, perhaps as a result
of the higher Immune activation and immunosenescence pre-
sent in vertically HIV-1-infected patients whose immune system
has developed in the presence of the virus since birth or
pregnancy [20]. This highlights the importance of close moni-
toring for prompt virus detection and early treatment world-
wide, particularly in resource-limited countries, where
molecular diagnosis and HIV monitoring, including resistance
genotyping [8] and ART, are still limited [21].
The most frequent DRMs to NRTIs were T215YFVI, D67N,
M41L and L210W. In fact, T215Y substitution causes inter-
mediate resistance to AZT and was a marker for patients with
immunodeﬁciency in the early 1990s [11,22]. M41L causes
resistance to AZT and d4T. K103N was the predominant DRM
to NNRTIs, with little or no effect on replication capacity [23].
It is a nonpolymorphic mutation selected in patients receiving
NVP and EFV [24] approved in Spain in 1998 and 1999,
respectively. L90M, M46I and V82A were the most prevalent
DRMs to PIs. L90M reduces susceptibility to all PIs except TPV
and DRV. V82A/C associated with mutations in positions 46Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inand 48 at protease [11] involves resistance to RTV and IDV
[11]. In our study, although some children recovered suscep-
tibility to EFV and NVP, we cannot exclude the possibility that
these resistance variants were at undetectable levels by stan-
dard sequencing, being selected if these children were reex-
posed to EFV and NVP, acquiring again resistance.
Virologic failure is common in children under ART as a result
of their long history of therapy, with frequent regimen switches
and high drug experience—more extensive than in adults [14].
A higher rate (80%) of these children have been exposed to off-
label drugs during their clinical follow-up compared to the pre-
viously reported rate (69%) (Férnandez Cooke et al., personal
communication). This is due to the existence of a lag between
the development and implementation of ARV, which increases
the risk of underdosing and consequently DRM selection. The
new Paediatric Research Plans encourage the development of
clinical trials with new ARV at the same time as their develop-
ment in adults (http://www.emea.europa.eu/docs/en_GB/
document_library/Other/). Resistance to new ART drug fam-
ilies was not analysed in our study because these therapies are
still limited in the treatment of HIV paediatric infection [14].
However, new-entry inhibitors or integrase inhibitors will play
an important role in the treatment of highly pretreated children
and perinatally infected young adults with multidrug resistance.
Despite the selection of HIV-1 resistance mutations to the
three main antiretroviral families in our pediatric cohort, some
drugs maintained their susceptibility (rates of >30%), mainly the
new PIs (tipranavir and darunavir) and NNRTIs (etravirine and
rilpivirine). Data will help to improve clinical management of
HIV-infected children carrying triple resistance in Spain and tofectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e1–605.e9
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nations. However, this requires maintenance of their clinical and
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